Recce Pharmaceuticals Ltd (RCE) — Cash Flow-to-Debt Ratio
Recce Pharmaceuticals Ltd (RCE) has a Cash Flow-to-Debt Ratio of 0.01x as of June 2026, meaning its operating cash flow of AU$341.10K could theoretically repay 0% of its total liabilities (AU$25.25 Million) in one year. See RCE FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Recce Pharmaceuticals Ltd Cash Flow-to-Debt Ratio (2014–2026)
Historical debt coverage capacity for Recce Pharmaceuticals Ltd across 13 annual periods. For the full cash flow conversion analysis, see Recce Pharmaceuticals Ltd cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Recce Pharmaceuticals Ltd (2014–2026)
Year-by-year debt coverage analysis for Recce Pharmaceuticals Ltd. Check RCE cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (AUD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2026 | -0.39x | AU$-9.89 Million | AU$25.25 Million | ▲ +70.4% |
| 2025 | -1.32x | AU$-20.44 Million | AU$15.47 Million | ▼ -61.5% |
| 2024 | -0.82x | AU$-13.01 Million | AU$15.89 Million | ▲ +66.8% |
| 2023 | -2.47x | AU$-12.69 Million | AU$5.14 Million | ▲ +29.9% |
| 2022 | -3.52x | AU$-9.01 Million | AU$2.56 Million | ▲ +47.3% |
| 2021 | -6.67x | AU$-7.86 Million | AU$1.18 Million | ▼ -63.2% |
| 2020 | -4.09x | AU$-3.81 Million | AU$931.53K | ▼ -107.8% |
| 2019 | -1.97x | AU$-2.61 Million | AU$1.33 Million | ▲ +49.0% |
| 2018 | -3.86x | AU$-1.73 Million | AU$448.82K | ▼ -35.1% |
| 2017 | -2.86x | AU$-2.50 Million | AU$874.44K | ▲ +63.3% |
| 2016 | -7.77x | AU$-1.61 Million | AU$206.80K | ▼ -615.3% |
| 2015 | -1.09x | AU$-296.14K | AU$272.47K | ▼ -2038.1% |
| 2014 | 0.06x | AU$11.43K | AU$203.81K | — |